Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released
An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.
The interim analysis assessed 468 cases of symptomatic COVID-19 among 44,325 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States. The investigational vaccine was reportedly 66% effective at preventing the study’s combined endpoints of moderate and severe COVID-19 at 28 days post-vaccination among all volunteers, including those infected with an emerging viral variant. Moderate COVID-19 was defined as laboratory-confirmed SARS-CoV-2 plus either one of the following: evidence
The largest HIV health care unit in Alabama and one of the country’s preeminent HIV clinics has relocated to state-of-the-art space in Birmingham’s Lakeview district.
The University of Alabama at Birmingham 1917 Clinic, the largest HIV health care unit in Alabama and one of the country’s preeminent HIV clinics, has relocated to the Dewberry Building located at 3220 Fifth Ave. South in Birmingham’s Lakeview district. It opened its new doors to the community and more than 3,600 active patients Dec. 15.
In its new location, the 1917 Clinic has 50,664 feet of space, a substantial upgrade from the previous clinic located on 20th Street South, which was deemed no longer a sustainable option for the needs of the clinic in 2019. The clinic will be increasing from 13 exam rooms and one procedure room to 27 exam rooms, two procedure rooms and four clinic offices dedicated for mental health/substance use counseling services.